Umstrittener Eingriff in die Natur

Geschlechtswahl.

10. November 2012, KURIER

Auf Zypern können Eltern das Geschlecht ihres Kindes bei einer künstlichen Befruchtung        vorherbestimmen lassen – auch Paare aus Österreich nehmen das in Anspruch 

Auch Paare aus Österreich fahren ins Ausland, um gezielt das Geschlecht des Kindes zu bestimmen. „Wir hatten erst vor kurzemein Paar aus Österreich bei uns. Es hat bereits drei 

Buben im Alter von ca. 8 und 4JahrensowieachtMonaten. Jetzt wollten sie ein Mädchen. 

Die Frau ist bereits schwanger – mit einem Mädchen.“ Umit Inak ist für Patientenange-legenheiten im Dogus IVF Centre in Nordzypern zuständig. „30 bis 40 Paare “aus Österreichseienin den vergangenen zwei Jahren in das Zentrum gekommen – zur Geschlechtsbestimmung („sex selection“) des Nachwuchses. Dem Großteil (rund 80 Prozent) gehe es dabei um „family balancing“:„Sie wollen ihre Familien gezielt durch einen 

Buben oder ein Mädchen vervollständigen“, so Inak. Nur bei einem kleinen Teil sollen mit der gezielten Geschlechtswahl genetische Erkrankungen verhindert werden. 

Kosten: Rund 6000 €. 

Zypern (sowohl der NordenalsauchderSüden) isteinesderwenigenLänderEuropas, in denen das uneingeschränkt erlaubt ist. In Österreich ist es verboten. 

Um praktisch 100-prozentigen Erfolg zu haben, ist eine künstliche Befruchtung (IVF) notwendig. Bevor die Embryos in die Gebärmutter eingesetzt werden, wird mittels „Präimplantationsdiagnostik“ (PID) das Geschlecht anhand einer Chromosomenanalyse bestimmt. Um die Anzahl von Embryonen des gewünschten Geschlechts zu erhöhen, führen Kliniken auf Zypern oder in den USA vorab eine „Spermiensortierung“ durch. 

Spermientrennung 

Mittels technischer Sortierverfahren werden die Spermien in jene mit X-oder Y-Chromosom (siehe Grafik) getrennt. Doch dieses Sortieren funktioniert nicht hundertprozentig, es können trotzdem Embryonen des „falschen“ Geschlechts entstehen. – „Es ist ethisch nicht vertretbar, gesunde Embryonen zu vernichten, weil sich das falsche Geschlecht haben“, kritisiert Univ.-Prof. Andreas Obruca vom Kinderwunschzentrum im Goldenen Kreuz in Wien. 

„Die Entscheidung, was damit passiert, liegt bei den Eltern“, sagt hingegen Umit Inak: „Es sind schließlich ihre Embryonen.“ 

„Die Paare, die ,family balancing‘ wollen, müssen uns ein Konzept vorlegen, was mit den Embryonen des anderen Geschlechts passieren soll. Wir werfen nicht einfach Embryonen weg, nur weil sie nicht in die Familienplanung passen“, sagt der deutsche Gynäkologe Peter Erich Hermann. Eristmedizinischer Direktor der Geniplet-Klinik auf Palma de Mallorca. 

Diese berät Paare mit Kinderwunsch aus europäischen Ländern, in denen bestimmte Behandlungen(z. B. Eizellspende) verbotensind– und organisiert diese im Ausland. 

„Die Paare können die Embryonen zum Beispiel zur  freigeben – die Nachfrage ist sehr groß.“ 

Wenig Nachfrage

Österreichische IVF-Institute verzeichnen „nur wenige Anfragen“ zur Geschlechterwahl–

und verweisen Interessenten an ausländische Kliniken. „Wir haben zwei Anfragen im Jahr“, sagt Obruca. „Bei uns sind es zwei bis drei“, so Univ.-Prof. Wilfried Feichtinger vom Wunschbabyzentrum: „Bei mir war einmal ein Landwirt mit sechs Töchtern, der wollte auch einen Sohn. Ich sehe nicht ein, warum in solchen Fällen die Geschlechterwahl nicht erlaubtist. EsgebeStudien,wonach es bei einer Zulassung von „family balancing“ in der westlichen Welt zu keiner Verschiebung des Geschlechterverhältnisses komme. 

In der Bioethikkommission beim Bundeskanzleramt gibt es allerdings eine breite Ablehnung: „Das ist nicht akzeptabel“, sagt die Vorsitzende, Christiane Druml: „Schließlich gibt es keine medizinischeNotwendigkeitdafür. Diese Form des Eingriffs indas Schicksalhat keinen vitalen Wert.“ Etwas anderes sei ein (in Österreich derzeit ebenfallsverbotener) Einsatz der Präimplantationsdiagnostik bei geschlechtsgebundenen Erbkrankheiten wie Hämophilie, die hauptsächlich bei Männern auftritt: Hier könnte in bestimmten Fällendurch dieWahldesGeschlechtsdieErkrankungvermieden werden.

UK limitations for high risk IVF patients‏

(El Mundo) Starting today, couples seeking a solution to their infertility in social security in a Scottish region have to be aware that they may be rejected if they satisfy two characteristics: be smokers or that women are considered obese by doctors.

Thus enters into force a controversial move, announced by the National Health Service (NHS) just 10 days ago, and further including other restrictions, such as limiting the number of attempts to achieve parenthood to two instead of the three that are held in the rest of UK.

The story, described as "very bad for patients" by the patient organization Infertility Network (the largest in the UK) is, however, accompanied by another very good in a crisis, since it will veto Scottish IVF in obese and smoking has, an allocation of £ 100,000 to fund infertility treatments, which will be invested in reducing waiting lists, also reported infertility Network.

Indeed, the extent of decrease from three to two attempts at IVF funded public health, is part of an attempt to get limited to 12 months as the maximum time that a couple should wait to receive assisted reproduction treatment.

What has upset the patient organization is that Scottish county implement these restrictive measures, just as the National Institute for Clinical Excellence (NICE) has recommended to the NHS expand the application criteria of assisted reproductive techniques.

Thus, the NHS funded IVF to women up to 42 years against 39 current limit. The NICE recommendations say anything to limit treatments obese women and smokers, although experts recognize that both qualities reduce chances of success in this type of therapy.

----------------------------------------------------------------------------------------------------------------------------------

Martes, 2 Octubre, 2012 

(El Mundo) A partir de hoy, a las parejas que busquen una solución a su infertilidad en la seguridad social de una región escocesa, la de Fife (es donde está situada la conocida universidad de St. Andrews, donde estudiaron los príncipes de Inglaterra Kate y William) han de tener en cuenta que se les podrá rechazar si cumplen dos características: ser fumadores o que la mujer esté considerada obesa por los médicos.

Entra así en vigor una polémica medida, anunciada por el Servicio Nacional de Salud (NHS) de Fife hace apenas 10 días, y que incluye además otras restricciones, como limitar el número de intentos para conseguir la paternidad a dos en lugar de los tres que se llevan a cabo en el resto de Reino Unido.

La noticia, calificada de "muy mala para los pacientes" por la asociación de pacientes Infertility Network (la más importante de Reino Unido) viene, sin embargo, acompañada de otra muy buena, ya que el mismo Gobierno escocés que vetará la fecundación in vitro en obesas y fumadores ha recibido, en plena crisis, una dotación de 100.000 libras para financiar tratamientos de infertilidad, que se invertirán en la reducción de las listas de espera, según informó también Infertility Network.

Precisamente, la medida de disminuir de tres a dos los intentos de fiv financiados por la sanidad pública, se enmarca en un intento de conseguir limitar a 12 meses el tiempo máximo que una pareja deberá esperar para recibir su tratamiento de reproducción asistida.

Lo que más ha molestado a la asociación de pacientes es que este condado escocés ponga en marcha dichas medidas restrictivas, justo cuando el Instituto Nacional de Excelencia clínica (NICE) ha recomendado al NHS ampliar los criterios de aplicación de técnicas de reproducción asistida. Así, el NHS financiará la fiv a mujeres de hasta 42 años, frente al limite de 39 actual. Las recomendaciones del NICE nada decían de limitar los tratamientos a mujeres obesas y fumadores, aunque los expertos reconocen que ambas cualidades disminuyen las posibilidades de tener éxito en una terapia de este tipo.

HIV CAN BE CURED

Jean Marie Andrie (Nobel prize candidate) - News from 5th NESA Inrternational Surgical Conference 

Université Paris-Descartes, Paris, France

In acute viral infections (such as poliomyelitis, smallpox, measles, Hepatitis B and many others), the virus entering the body for the first time proliferates in its target cells; at the same time, it induces neutralizing antibodies that, although they develop too late to prevent the pathology, eventually eradicate the virus and neutralize any further attack by the same virus. Such viral infections are vaccinable with compositions that are generally made of inactivated virus (or chosen parts of it) and of an adjuvant amplifying the antibody production. Such vaccines generate antiviral antibodies that  neutralize and eradicate the virus before it attacks its target cells.

HIV infection is not a vaccinable infection since the antiviral antibodies raised during the primary infection result in a viral control which is only partial and transitory ; the result is a progressive destruction of the immune system that ends eventually in the various fatal manifestations of  HIV.  Faced to the challenge of that apparently non-vaccinable infection, vaccinologists have tried over the last 25 years to develop prototypes incorporating newly identified viral peptides/epitopes (or their DNA sequences) susceptible to play a role in the infectious process. 

So far, however, their efforts were unsuccessful. In the present talk, I will describe the alternative approach I developed over the last 5 years with my colleague Wei Lu. We based our  research on the observation that a very small percentage (<1%) of HIV-infected patients as well as some SIV-infected macaques  (identified as elite controllers or “EC”) have a strong but non-antibody-dependant control of virus replication (despite the virus still latently infects the nucleus of their target CD4+T-cells).

First, we showed that SIV replication of EC manaques was suppresed by a set of T regulatory cells with a CD8 phenotype. We then developed a new type of vaccine thatdoes not induce SIV-specific antibodies but SIV-specific regulatory CD8+T-cells. We showed that vaccinated monkeys were protected for >1 year from several SIV challenges. It remains to know whether such a suppressive T-cells vaccine is transferable in humans to prevent and treat HIV infection.

New communication service to GENIPLET patients

Our treatments are highly indivdual and require constant direct contact between the International Department, e.g.  Dimitrina Lisichkova, your attending physician and you as a patient. We will need ready access to you. Often during the preparation and treatment rapid  and urgent decisions are required. We therefore collect all available telephone numbers, email addresses, Skype, WhatsApp, SMS etc.

Please ensure that you are always reachable.

The communication contains medical information and treatment instructions. This must be documented in your electronic file. This requires that we focus on Telephone / Skype and email. These are automatically stored in your file. Other means of communication are not well suited for it, and should be used only in exceptional cases.

Full telephone calls should be kept always by appointment not to disturb our work and talking with other patients. Announce this please always with Dimitrina.

If you are overseas, it is imperative that we reach you by mail. So you should create a way to have access to the email account known to us. This is uncompfortable when using the local SIM cards due to overpriced roaming charges. It is recommended that  You buy in each country a prepaid - SIM card with a flat rate for data traffic.

Once you are in Mallorca we can recommend a partner who hires You a small portable wireless  router. You can book in advance on our and his website. He will then deliver it to the clinic for you. It and can be used during your stay with an affordable flat rate with costs from 5.70 to 10 € per day at any time with Internet availability for all WLAN - establish appropriate devices. These are for example Smartphones (eg iPhone) or laptops and tablets (eg iPad). You can use VOIP like Skype etc. quite normal. So you can leave the expensive roaming function of your devices turned off and get reached for us as well as for your personal or business contacts at any time via email or Skype.

Before departure bring WIFIrental router back at us. Book before you travel or even if you already here on the island, by putting in. Use our promotional code, you will get 5% discount on the offer price. The payment to be settled directly with the company WIFIrental Travel (www.wifirental.travel).

We have agreed with the seller for a discount of 5% off for our patients at the normal price.

http://www.geniplet.com/kliniken/klinik-palma/reise-service-palma/kommunikation/

http://www.geniplet.com/patienten/kommunikation/

EU-Parlament: Zell- und Gewebespenden nicht kommerzialisieren

http://www.abc.es/20120911/sociedad/abci-parlamento-europa-prohibir-venta-201209111813.html

http://www.aerzteblatt.de/nachrichten/51598/EU-Parlament-Zell-und-Gewebespenden-nicht-kommerzialisieren

http://www.ots.at/presseaussendung/OTS_20120911_OTS0149/seeber-zu-zellspenden-kein-kommerz-mit-dem-menschlichen-koerper

The plenary session of the European Parliament adopted by 551 votes to 14, with 81 abstentions, a ban of financial incentives for cell donation: also sperm and egg. Only a cost replacement for lost work time and other expenses should be allowed. Basically, this is already in place in Spain since 1985. The problem is centered about the anonymity. The EU has a strict aim of banning the donors anonymity.

This was realized in England many years ago. The result has been disastrous. Hence, in England there are almost no more fresh or frozen donor eggs. Nobody wants to get into the risk of being outed. This risk has compensated by money. It benefits no one, if the pure doctrine is guideline, but donation is not longer available for all and everybody has to travel abroad. Another problem is that: in countries with high wage level, the cost reimbursement is not sufficient enough to motivate young women, for this there is a serious interference with their physical integrity, including all the related emotional stress. For Spain, on the contrary with its relatively low wages, may be enough.

This must be separated with organ donations that serve the preservation of life and, those that create a new life. Much higher is the concern of top healthy gamete donors. No question, if you're not a pay deceased organ donor and his descendants. Or, possibly, even the executive organ donation, the donor organizations and their doctors.

In the gametes cells (i.e., egg and sperm) which produce the genetic offspring of a donor, their personal involvement is much higher and for that also be reimbursed. Because it can have clear adversely affect on health and in social coexistence for donors during their ongoing life. Mr. Liege, a German politician in Brussels, who has sometimes shown an interest in the health and well-being (and proposed this Act in the Parliament), and he simply has not thought enough.

If the EU continues on this wrong path, both remove the anonymity from prohibiting the compensation for services, and on the correction of a completely out of control current demographic structure, this service will move to non-European regions. In that way, such as in Spain, the legal certainty will be lost, and it becomes more expensive. In any case, the rich will certainly get some benefit from this method.

What is lacking in the political process of sufficient research and consulting. There is another example of the increasingly poor quality of political work. Spain can be proud of its parliament that in 1985 approved the current reproductive law, shortly after the end of dictatorship.

In any case and in any time, the Geniplet Group can already offer outside the EU, egg and sperm donation with the usual high quality without being exposed to the European regulatory frenzy. We are committed exclusively to the quality in the interest of our patients and our overarching ethical principles. Of course, we strictly observe the legal regulations of the different countries, although they might be nonsensical.

Dr.P.Hermann

Medical Director

Geniplet Palma Reproductive Clinic

Das Plenum des Europäischen Parlaments hat mit 551 gegen 15 Stimmen bei 81 Enthaltungen ein Verbot der Zellspende, auch Samen und Eizellen, gegen Honorar empfohlen. Es soll lediglich ein Kostenersatz für entgangene Arbeitszeit und sonstige Unkosten zulässig sein.

Im Grunde ist dies in Spanien bereits so eingeführt.

Das Problem liegt aber in der Anonymität. Die EU hat das strikte Ziel, die Anonymität der Spende zu verbieten. Dies wurde in England vor vielen Jahren verwirklicht. Die Folge davon ist fatal. Es gibt in England seither fast keine frischen Eizellspenden mehr. Niemand will sich in die Gefahr bringen, geoutet zu werden. Dieses Risiko muss erkauft werden. Es nützt niemandem, wenn zwar die reine Lehre verfolgt wird, die Spende aber damit nicht mehr verfügbar wird und nahezu alle, die sie benötigen, ins Ausland reisen müssen. 

Ein weiteres Problem ist, dass in Ländern mit hohem Lohn-Niveau ein reiner Kostenersatz nicht ausreicht, um genügend junge Frauen zu diesem schweren Eingriff in ihre körperliche Integrität samt all den damit zusammenhängenden emotionalen Belastungen, zu motivieren. Für Spanien mit seinen relativ niedrigen Löhnen mag das ausreichen.

Es muss auch strikt getrennt werden zwischen Organ - Spenden, welche dem Erhalt von bestehendem Leben dienen , und solchen Spenden, welche neues Leben erzeugen. Ungleich höher ist die Betroffenheit der ja top - gesunden Gametenspender. Keine Frage, dass man einen verstorbenen Organspender und seine Nachfahren nicht bezahlen soll. Möglicherweise auch nicht die ausführenden Organe einer Organspende, Organisationen und Ärzte. 

Bei Gameten, Eizellen und Samenzellen, welche genetische Nachkommen der Spender erzeugen, ist die persönliche Betroffenheit der Spender ungleich höher und damit auch zu vergüten. Denn selbstverständlich können sich nachteilige Auswirkungen gesundheitlich und auch im sozialen Zusammenleben für die Spender ergeben. Herr Liese, ansonsten ein kenntnisreicher guter Gesundheitspolitiker aus Deutschland in Brüssel, hat hier einfach nicht zu Ende gedacht.

Falls die EU also auf diesem falschen Weg weiter voranschreitet, sowohl die Anonymität aufzuheben als auch die Entschädigung für den Dienst an der Korrektur einer völlig aus dem Ruder laufenden demographischen Struktur zu verbieten, wird sich dieser Service ins aussereuropäische Umland verlagern. Damit geht die Rechtssicherheit wie z.B. in Spanien verloren, es wird teurer und die Methode steht nur mehr den leistungsfähigeren Bevölkerungsschichten zur Verfügung.

Hier fehlt es im politischen Prozess an ausreichender Recherche und Beratung. Ein weiteres Beispiel für die zunehmend schlechtere Qualität politischer Arbeit. Spanien kann stolz sein auf sein Parlament welches das aktuelle Reproduktions-Gesetz 1985, kurz nach Ende der Diktatur, auf den Weg gebracht hat.

GENIPLET jedenfalls hat sich darauf eingerichtet und kann bereits jetzt  jederzeit auch ausserhalb der EU Eizellspenden und Samenspenden mit der gewohnt hohen Qualität anbieten ohne der Europäischen Regelungswut ausgesetzt zu sein. Wir sind ausschliesslich der Qualität im Interesse unserer Patienten und unseren übergeordneten ethischen Grundsätzen verpflichtet. Selbstverständlich beachten wir die gesetzlichen Regelungen in den einzelnen Ländern streng, so unsinnig sie auch sein mögen.

Dr.P.Hermann

Medical Director

Geniplet Palma Reproductive Clinic

La sessione plenaria del Parlamento europeo ha approvato con 551 voti favorevoli contro 14, e 81 astensioni, il divieto di incentivi finanziari per la donazione di cellule: sperma e uova. Potranno essere consentiti solamente i costi per il lavoro perso e altre spese affini. In pratica, tutto ciò è già in vigore in Spagna dal 1985. Tuttavia, il punto focale riguarda l'anonimato. L'Unione Europea ha come chiaro obiettivo vietare l’anonimato per i donatori.

Questo è stato effettuato in Inghilterra molti anni fa e il risultato è stato disastroso. Infatti, in Inghilterra non ci sono quasi più ovuli freschi o surgelati. Nessuno vuole correre il rischio di uscire dall’anonimato ed è per questo, che il rischio dovrebbe essere compensato in denaro. Non giova a nessuno, se la pura teoria verrà usata come linea guida, di certo, la donazione non sarà più accessibile a tutti e quindi si dovrà viaggiare all'estero. Un altro problema è che nei Paesi con un alto tasso salariale, il rimborso dei costi non è sufficiente a motivare le giovani donne, dato che questo processo implica una grave interferenca nella loro integrità fisica, e un correlato forte stress emotivo. Al contrario in Spagna, con i suoi salari relativamente bassi, il rimborso dei costi potrebbe essere sufficiente.

Si devono tenere separate dalle donazioni di organi, quelle che servono a preservare a vita da quelle che servono a crearne una nuova. Maggiore poi è la preoccupazione per i donatori sani di gameti. Non c’è nessuna alternativa, se non sei un donatore (pagante) di organi deceduto o uno dei suoi discendenti. O, possibilmente, nemmeno la donazione di organizi esecutiva, le organizzazioni di donatori e relativi medici.

Se l'Unione Europea continuerà su questa strada sbagliata, togliendo l'anonimato per i donatori e vietando la compensazione il servizio, per correggere l’attuale struttura demografica completamente fuori controllo, questo tipo di servizio si sposterà verso aree non europee. In questo modo, come ad esempio per la Spagna, la certezza del diritto verrà perduta, e il tutto diventerà più costoso. In ogni caso, le persone ricche saranno certamente le uniche che otterranno qualche beneficio da questa situazione.

Quello che manca nel processo politico è una ricerca e una consulenza adeguata. Questo è un altro esempio della sempre peggiore qualità del lavoro politico. La Spagna può essere orgogliosa del proprio parlamento che nel 1985, poco dopo la fine della dittatura, approvò la sua attuale legge sulla riproduzione.In ogni caso e in qualsiasi momento, il Gruppo Geniplet può già offrire, al di fuori dell'UE, la donazione di ovuli e di sperma con la sua consueta ed elevata qualità senza essere esposto alla frenesia normativa europea. Ci dedichiamo esclusivamente alla ricerca della qualità nell'interesse dei nostri pazienti e rispettanto i nostri solidi principi etici. Naturalmente, osserviamo pedisequamente le disposizioni normative dei diversi Paesi, anche se potrebbero essere prive di senso.
Nelle cellule di gameti (cioè, uova e sperma) che portano alla nascita la prole genetica di un donatore, il loro coinvolgimento personale è molto più alto e anche per questo lo sarà anche il rimborso. Perché potrebbe avere un chiaro effetto negativo sulla loro salute e può coesistere socialmente con i donatori durante il corso della loro vita. Il sig. Liese, un politico tedesco a Bruxelles, che ha altre volte mostrato un interesse per la salute e il benessere (e ha proposto questo al in Parlamento), semplicemente non ci ha riflettuto abbastanza.

Dr.P.Hermann

Medical Director

Geniplet Palma Reproductive Clinic

Found a new pregnancy hormone

Maternal pregnancy hormone HCG - possible marker for susceptibility

A breakthrough discovery in Leipzig: Source for HCG is not only the trophoblast of the embryo, but also the maternal endometrium. Both forms are encoded by different genes and are distinguishable.

This has several practical implications for the treatment of infertility. On the one hand this could be an explanation for the so-called biochemical pregnancies. I.e. volatile HCG - increases with decrease in the zero-field after a few days. This comes because the usual HCG tests measure the different versions of HCG both together. This is therefore probably not an early miscarriage, but a particularly strong HCG-producing endometrium in this cycle, despite there was no implantation. From this we can conclude that the embryo may have been in these cases even the reason for the failure, eg by aneuploidy.

The other important consequence of the discovery of the mother's HCG would be to take with regard to the optimal timing of implantation. If there are correlations between the receptivity of the endometrium and its HCG production we could perhaps be more accurately determining the implantation - window. We already know that this will not put up equally among all women. Only there are no reliable methods for the determination of this time window. Perhaps the endometrial HCG is a key to it. Further research to go.

Because we feel the ongoing research underestimated and for many years completely ignored we have invited  Prof. Alexander to the 5th NESA – Congress.

Mütterliches Schwangerschaftshormon - möglicher Marker für die Empfänglichkeit

Eine bahnbrechende Entdeckung aus Leipzig: Quelle für HCG ist nicht nur der Trophoblast des Embryo, sondern auch das mütterliche Endometrium. Beide Formen werden durch verschiedene Gen-Abschnitte kodiert und sind unterscheidbar.

Daraus ergeben sich mehrere praktische Folgen für die Sterilitätsbehandlung. Einerseits könnte dies eine Erklärung für die sogenannten biochemischen Schwangerschaften sein. D.h. flüchtige HCG - Erhöhungen mit Abfall in den Null-Bereich nach wenigen Tagen. Denn die üblichen HCG-Teste messen beide unterschiedlichen Varianten des HCG zusammen. Es könnte sich hierbei also nicht um einen sehr frühen Abort, sondern um ein besoneders stark HCG-produzierendes Endometrium in diesem Zyklus handeln, ohne dass es zu einer Einnistung gekommen ist. Daraus kann man schlussfolgern, dass möglicherweise der Embryo in diesen Fällen selbst den Grund für den Fehlschlag gegeben hat, z.B. durch Aneuploidien.

Die andere wichtige Konsequenz aus der Entdeckung des mütterlichen HCG wäre zu ziehen hinsichtlich des optimalen Implantationszeitpunkts. Falls es Zusammenhänge gibt zwischen der Empfänglichkeit des Endometriums und seiner HCG-Produktion liesse sich möglicherweise das Imlantationsfenster genauer bestimmen. Bereits heute wissen wir dass dies nicht bei allen Frauen gleichermassen aufgemacht wird. Nur gibt es noch keine verlässlichen Bestimmungsmethoden für dieses Zeitfenster. Vielleicht ist das endometrielle HCG ein Schlüssel dazu. Weitere Forschungen dazu sind unterwegs.

Weil wir diese seit vielen Jahren laufenden Forschungen als völlig unterbewertet und nicht beachtet hieltenn haben wir Herrn Prof. Alexander zum 5. NESA - Kongress nach Palma eingeladen .

Italian ban on embryo screening violated couple's rights

Rosie Beauchamp Progress Educational Trust [BioNews, London] Italy has violated the rights of a couple carrying cystic fibrosis by preventing them from screening embryos using PGD, the European Court of Human Rights (ECtHR) has ruled. The Strasbourg-based court ordered the Italian Government to pay the couple €17,500 in damages and expenses. Rosetta Costa and Walter Pavan found out that they were both healthy carriers of cystic fibrosis when they gave birth to a daughter with the condition in 2006. In 2010, the couple terminated another pregnancy on medical grounds when the fetus was found to have cystic fibrosis. The couple decided to have a second child using IVF with the intention of screening the embryos} using PGD to select an embryo without the condition. However, Italy is one of the few European countries, along with Austria and Switzerland, which prohibits the technique. The couple argued this prohibition interfered with their right to respect for their private and family life under the European Convention on Human Rights. Italy argues that its laws protect the health of women and children and discourage deliberate 'eugenic abuse'. However, the ECtHR ruled that the privacy rights of the couple trump that concern. The Court also said that the case highlights 'the incoherence of the Italian legislative system that bans the implantation of only healthy embryos while allowing the abortion of fetuses with genetic conditions'. The law 'only gives the plaintiffs one option, full of anxiety and suffering', it said. The Italian Government said on Wednesday that it was likely to appeal the ruling. However, Antonio Di Pietro, head of an opposition party, Italy of Values, said that Italy needed a new law that 'gives the right to have preliminary genetic analysis of an embryo not just for sterile couples but also to fertile couples suffering from hereditary diseases such as sickle cell anaemia and cystic fibrosis'. The case is Costa and Pavan v. Italy (application no. 54270/10).

Speech topics of Dr. Peter E.Hermann, GENIPLET - in NESA International Surgicial Conference, - Palma de Mallorca

OUT OF MAINSTREAM ART. HOW TO DECIDE ABOUT MEDICAL, LEGAL AND ETHIC BORDERLINE CASES.

Dr. Peter Hermann MD

While the world is becoming complex, new groups that were not accepted and that were facing suppression before are gaining their rights. Following this process we are confronted with the resulting questions concerning reproduction.

There are countries where even basic treatment modalities such as egg donation are no issue. This includes the German-speaking countries. We at Geniplet Group have been confronted for many years with many additional requirements. Besides classical egg donation, the issues we confront are:

• How do we treat women without a uterus who desire pregnancy through surrogacy?
• How should we respond to requests of singles without a partner who are "running out of time"?
• How can we help couples over 40 and 50 in second and third relationships that consult us for infertility and are in good health (a typical problem in Switzerland)?
• Same-gender couples and their constitutionally guaranteed rights for equal treatment 
• Should we help transsexuals?
• What do we do with sex-linked abnormalities at the time when we can offer an ethically acceptable pre-conception sperm selection?

New diagnostic methods make it possible to preserve fertility even with diminished ovarian reserve when diagnosed at young age. Identical the situation of the men knowing that the older than 40 will have an increasing number of mutations with psychological and psychiatric risks to the child as a consequence. Decisions are made which influence future profession and career. But these procedures also allow to preserve healthy gametes for a further use. This means at the end a desynchronization of chronologic age and gamete quality which helps to prolong the fertile phase.

We will try to answer these questions while functioning in the context of a substantial loss of tension between ethical and sectarian beliefs in the Western world and aggressively roaring archaic rule claim on our doorstep.

GENIPLET in 5th NESA International Surgicial Conference

Palma de Mallorca, 13-15 September,2012 at Gran Hotel Melía Victoria

We are co-founders of the NESA (New European Surgical Academy). This organization was founded in 2004 in Berlin. Founder and driving force is our Member of the Scientific Board, Prof. Michael Stark.

To celebrate the completion of our hospital in Palma (Geniplet Palma Reproductive Clinic) Mallorca was a selected as destination for the 5th Annual congress.

13th to 15th of August  2012 there gathered approximately 220 participants from the whole world, from 26 countries, and 14 invited speakers on the latest advances in the field of robotics, obstetrics, surgical gynecology and reproductive medicine.

The event was  supported by the Geniplet AG. The conference papers will be bublished in Geniplet - blog.

Our presentation did discuss borderline cases of ART. This is the core competence of Geniplet; For every problem to have a solution in one of our activities in different countries.

Since we have to lament a construction delay, the opening of our clinic is not yet possible. We're already preparing another specific event in May 2013 under the title THINK - TANK BALEAR. We will be hence honored to inivite later again for the physical opening of our clinic.

Wir sind Gründungsmitglieder der NESA (New European Surgical Academy). Diese Organisation wurde 2004 in Berlin gegründet. Gründer und treibende Kraft ist unser Mitglied des Scientific Board, Prof. Michael Stark.

Aus Anlass der Fertigstellung unserer Klinik in Palma (Geniplet Palma, Reproductive Clinic) wurde Mallorca als Ort für den 5. Jahres- Kongress ausgewählt.

Vom 13. bis 15. August trafen sich ca 220 Teilnehmer aus der ganzen Welt, aus 26 Ländern,  sowie 14 eingeladene Referenten um die neuesten Entwicklungen auf dem Gebiet der Robotik, der Geburtshilfe, der operativen Gynäkologie und der Reproduktionsmedizin auszutauschen.

Die Veranstaltung wurde von der GENIPLET AG unterstützt. Die Kongressbeiträge werden wir im Geniplet - Blog veröffentlichen.

Unser Vortrag wird Grenzfälle des Kinderwunsches behandeln. Dies ist die Kernkompetenz von Geniplet: Für jedes denkbare Problem eine Lösung in einer der Aktivitäten in verschiedenen Ländern anbieten zu können.

Da wir eine Bauverzögerung zu beklagen haben wird die Eröffnung unserer Klinik nicht zum Zeitpunkt des Kongresses möglich sein. Wir planen deshalb eine weitere spezifische Veranstaltung im Mai 2013 unter dem Titel THINK - TANK BALEAR und werden entsprechend einladen.

Links:

www.geniplet.com
www.uspnesadays.com
Congress Highlights
www.nesacademy.org